Research Radartracking 72 published studies · 21 human · 14 clinical trials · 14 cancer pages · updated Jun 2026Open the Research Map →

Serous Carcinomas

Auto-discovered from research; not yet curated.

Auto-added · review pending
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

OncoForge editorial · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Evidence at a glanceHuman · observationalReported positive
1 published studies that name Serous Carcinomas1 human studies (trial, observational, or meta-analysis)414 source documents in the Serous Carcinomas corpus
Why this grade?

Human · observational — Human observational evidence only — no trials.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Living document — last change June 9, 2026: New cancer type added.

Overview

Serous Carcinomas is tracked here from the published studies that mention it. This page shows the research evidence collected so far — it is not a curated clinical overview.

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
2
Meta-analysis
4
Systematic review
2
Randomized trial
0
Clinical trial
24
Observational
2
Case report
22
Review
358
Preclinical
0
Other
0

Evidence on specific compounds

How the published studies grade individual drugs, supplements, and other agents in Serous Carcinomas — each rated by how strong the evidence is, not a recommendation.

What recent studies report in Serous Carcinomas

These are reviewed studies whose abstracts concern Serous Carcinomas. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Serous Carcinomas. Most are early lab, animal, or small human studies, and findings often conflict.

1 study1 humanMechanism (1)

Tracking 1 published study of Serous Carcinomas: 1 in humans.

Reported direction across studies: 1 positive.

These counts summarize what the studies reported; they are not a measure of whether anything works for Serous Carcinomas.

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early human

The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma

BMC cancer · Jun 2015 · cell line experiments plus human tissue expression and survival analysis

ovarian epithelial carcinomaovarian cancermucinous ovarian tumorsserous carcinomas

This study looked at REG4 in ovarian epithelial carcinoma using SKOV3 cells and ovarian tissue samples. In cells, adding REG4 or making cells overexpress REG4 reduced apoptosis and increased proliferation, migration, invasion, and G2/S cell-cycle progression. In patient tissues, REG4 was more highly expressed in tumor samples than in normal ovarian tissue, and higher REG4 expression was linked with worse survival outcomes.

Key findings
  • REG4 overexpression and recombinant REG4 inhibited apoptosis in SKOV3 cells.
  • REG4 increased proliferation, migration, invasion, and G2/S progression in SKOV3 cells.
  • Wnt5a, p70s6k, survivin, and VEGF increased, while Bax decreased with REG4 overexpression.
  • REG4 mRNA and protein were higher in ovarian tumor tissues than in normal ovarian tissue.
  • Higher REG4 expression was associated with poorer cumulative and relapse-free survival.
Limitations: Primarily cell-line and tissue-expression study; no therapeutic intervention in patients.; Observational survival association cannot establish causality.; Abstract does not report sample sizes, effect sizes, or detailed statistical estimates.; Findings are based on one ovarian cancer cell line (SKOV3) and may not generalize to all ovarian cancers..

REG4 was studied as a biomarker and functional regulator in ovarian cancer, not as a repurposed drug or natural compound.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Browse all studies mentioning Serous Carcinomas →

Clinical trials in Serous Carcinomas

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →